USE OF RECALL IMMUNITY TO ENHANCE VACCINE EFFICACY IN THE ELDERLY

利用回忆免疫力增强老年人的疫苗效力

• 批准号: 7349836
• 负责人: ELLEN KRAIG
• 金额: $ 2.77万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349836
• 关键词: USE; RECALL; IMMUNITY; ENHANCE; VACCINE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a pilot study to test our recall memory immune enhancement protocol in a primate model. It takes advantage of a unique resource available in San Antonio, a cohort of aged baboons who were immunized against tetanus when they were young. We predict that these animals will have long-lived memory T cells specific for tetanus that will be able to provide ¿help¿ to B cells upon re-exposure to tetanus (or TTFC, the immunodominant fragment) when the animals are old. Moreover, by fusing a ¿new¿ antigen (never before seen by the baboon population) to TTFC, we predict that these memory T cells will be able to provide ¿help¿ to B cells specific for this ¿new¿ antigen as well. For the test antigen, we propose to use the LcrV protein from the human pathogen Yersinia pestis (plague). This will allow us a model in which we can test three parameters of vaccine efficacy: i) titer of the antibodyies produced to the ¿new¿ antigen, LcrV; ii) protective potentials of the antibodies produced; and iii) the amount of stimulation of T cells specific for the ¿recall¿ antigen (TTFC) vs. the ¿new¿ antigen (LcrV). If recall memory enhancement were successful, it would have numerous potential applications, including: vaccines for biodefense or for natural human pathogens, cancer vaccines, autoimmune regulation, and most particularly, for the improvement of vaccine protocols and immune-based therapies for use in our aging population.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一，该子项目和研究者 (PI) 可能已从其他 NIH 来源获得主要资助，因此可以在其他 CRISP 机构中得到体现。列出的是该中心，该中心不一定是研究者的机构。这是一项在灵长类动物模型中测试我们的回忆记忆免疫增强方案的试点研究，它利用了圣安东尼奥市（一群老年人）的独特资源。狒狒是谁我们预测，这些动物在年轻时就接种过破伤风疫苗，它们将具有针对破伤风的长寿命记忆 T 细胞，能够提供 ¿帮助当动物年老时再次暴露于破伤风（或 TTFC，免疫显性片段）时，B 细胞也可以通过融合 ¿新的抗原（狒狒群体以前从未见过）转化为 TTFC，我们预测这些记忆 T 细胞将能够提供 ¿帮助专门针对此的 B 细胞 ¿新的对于测试抗原，我们建议使用来自人类病原体鼠疫耶尔森氏菌（鼠疫）的 LcrV 蛋白，这将使我们能够测试疫苗功效的三个参数：i）产生的抗体滴度。到 ¿新的抗原，LcrV；ii) 产生的抗体的保护潜力；以及 iii) 对 ¿记起抗原 (TTFC) 与 ¿新的如果回忆记忆增强成功，它将有许多潜在的应用，包括：生物防御或天然人类病原体的疫苗、癌症疫苗、自身免疫调节，最特别的是，用于改进疫苗方案和基于免疫的疫苗。用于老龄化人口的疗法。